STOCK TITAN
  1. Home
  2. News
  3. Clinical Trials

Clinical Trials News LIVE

Our live news platform offers continuous updates on the most pivotal clinical trials taking place in the biotech sector. These updates are critical, as they can influence the stock market significantly, causing both rises and dips in biotech stock prices.

We cover the full spectrum of clinical trials, from early-stage investigations to late-stage pivotal trials. Whether it's surprising successes, unforeseen setbacks, or changes in timelines, we provide accurate and timely coverage to help you stay ahead.

Stay up-to-date with our live feed of clinical trial news in the biotech industry and understand how they shape the stock market landscape. Gain the edge you need in the rapidly evolving world of biotech investing.

The news is in real time for GOLD users while there is a 15 second delay for FREE users.

Become a Gold member to remove ads, unlock the feed filters, voice notification and see news without delay

70

NEWS
TODAY
check them out

1

NEWS ENHANCED BY
RHEA-AI
Who is Rhea? Read More
NEWS BY EXCHANGE
NYSE Nasdaq OTC

Stock News Live Feed

Today's News - Full List
Voice GOLD
Notifications GOLD
Sound ON - +
IMPACT
SENTIMENT
BNTX : Nasdaq
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
clinical trial
IMPACT
SENTIMENT
CCCFF : OTC
Carlyle Provides Phase 2 Drilling Strategy at Newton
clinical trial
IMPACT
SENTIMENT
TOL : NYSE
Toll Brothers Opens Phase II at Preserve at San Tan Community in Arizona
clinical trial
IMPACT
SENTIMENT
SLI : AMEX
Standard Lithium Files Definitive Feasibility Study for its First Commercial Lithium Extraction Plant – Phase 1A
clinical trial
IMPACT
SENTIMENT
ALBT : Nasdaq
Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis
partnership clinical trial
IMPACT
SENTIMENT
IMNN : Nasdaq
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
clinical trial
IMPACT
SENTIMENT
CBAY : Nasdaq
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
clinical trial
IMPACT
SENTIMENT
CRBU : Nasdaq
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
clinical trial
IMPACT
SENTIMENT
AIMLF : OTC
AI/ML Innovations Inc.’s Subsidiary Chosen as the Digital Technology Provider for an International Clinical Study Funded by European Commission
clinical trial AI
IMPACT
SENTIMENT
PTN : NYSE
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
clinical trial
IMPACT
SENTIMENT
HOOK : Nasdaq
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
clinical trial
IMPACT
SENTIMENT
CRVO : Nasdaq
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies
clinical trial
IMPACT
SENTIMENT
ATBPF : OTC
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
clinical trial
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
clinical trial
IMPACT
SENTIMENT
NTLA : Nasdaq
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
clinical trial
IMPACT
SENTIMENT
SAGE : Nasdaq
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
clinical trial
IMPACT
SENTIMENT
IMRN : Nasdaq
Immuron Announces Travelan® Clinical Study Cohort 2 commences
clinical trial
IMPACT
SENTIMENT
GILD : Nasdaq
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
clinical trial
IMPACT
SENTIMENT
TAK : NYSE
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
clinical trial
IMPACT
SENTIMENT
ORIC : Nasdaq
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
conferences clinical trial
IMPACT
SENTIMENT
VKTX : Nasdaq
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
clinical trial
IMPACT
SENTIMENT
YMAB : Nasdaq
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
clinical trial
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
clinical trial
IMPACT
SENTIMENT
BMY : NYSE
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
clinical trial
IMPACT
SENTIMENT
BMY : NYSE
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
clinical trial
IMPACT
SENTIMENT
MBOT : Nasdaq
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
clinical trial
IMPACT
SENTIMENT
SLS : Nasdaq
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
conferences clinical trial
IMPACT
SENTIMENT
BMEA : Nasdaq
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
clinical trial
IMPACT
SENTIMENT
KA : Nasdaq
Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
clinical trial
IMPACT
SENTIMENT
ABVC : Nasdaq
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
clinical trial
IMPACT
SENTIMENT
NXTC : Nasdaq
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
clinical trial
IMPACT
SENTIMENT
OCEA : Nasdaq
Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics
clinical trial
IMPACT
SENTIMENT
PRME : Nasdaq
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
clinical trial
IMPACT
SENTIMENT
NKGN : Nasdaq
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
clinical trial
IMPACT
SENTIMENT
LSTA : Nasdaq
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer 
clinical trial
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
clinical trial
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
clinical trial
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
clinical trial
IMPACT
SENTIMENT
NKTX : Nasdaq
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
clinical trial
IMPACT
SENTIMENT
CRNX : Nasdaq
Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma
clinical trial
IMPACT
SENTIMENT
EVLO : Nasdaq
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
clinical trial
IMPACT
SENTIMENT
BOLT : Nasdaq
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
clinical trial
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
conferences clinical trial
IMPACT
SENTIMENT
GLUE : Nasdaq
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
clinical trial
IMPACT
SENTIMENT
IDYA : Nasdaq
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
clinical trial
IMPACT
SENTIMENT
TEVA : NYSE
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
clinical trial
IMPACT
SENTIMENT
GMDA : Nasdaq
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
clinical trial
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
clinical trial
IMPACT
SENTIMENT
HALO : Nasdaq
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
partnership clinical trial
IMPACT
SENTIMENT
GEHC : Nasdaq
GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence
clinical trial
Today's News - Full List